Literature DB >> 10466799

Mapping of domains on the human parainfluenza virus type 2 nucleocapsid protein (NP) required for NP-phosphoprotein or NP-NP interaction.

Machiko Nishio1, Masato Tsurudome1, Morihiro Ito1, Mitsuo Kawano1, Shigeru Kusagawa1, Hiroshi Komada1, Yasuhiko Ito1.   

Abstract

The epitopes recognized by 41 monoclonal antibodies directed against the nucleocapsid protein (NP) of human parainfluenza virus type 2 (hPIV-2) were mapped on the primary structure of the hPIV-2 NP protein by testing their reactivities with deletion mutants. By Western immunoblotting using these monoclonal antibodies, the analysis of deletion mutants of the hPIV-2 NP protein was performed to identify the region essential for NP-NP interaction and phosphoprotein (P)-binding sites on the NP protein. The results indicate that the N-terminal 294 aa of the NP protein are all required for NP-NP self-assembly, and that two C-terminal parts of the NP protein are essential for NP-P binding: one region, aa 295-402, is required for binding to the C-terminal part of the P protein and another region, aa 403-494, to the N-terminal part of the P protein.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10466799     DOI: 10.1099/0022-1317-80-8-2017

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  12 in total

1.  Functional mapping of the nucleoprotein of Ebola virus.

Authors:  Shinji Watanabe; Takeshi Noda; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

2.  Mapping of the VP40-binding regions of the nucleoprotein of Ebola virus.

Authors:  Takeshi Noda; Shinji Watanabe; Hiroshi Sagara; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

3.  Oligomerization of Hantavirus N protein: C-terminal alpha-helices interact to form a shared hydrophobic space.

Authors:  Pasi Kaukinen; Vibhor Kumar; Kirsi Tulimäki; Peter Engelhardt; Antti Vaheri; Alexander Plyusnin
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  A Point Mutation in the RNA-Binding Domain of Human Parainfluenza Virus Type 2 Nucleoprotein Elicits Abnormally Enhanced Polymerase Activity.

Authors:  Yusuke Matsumoto; Keisuke Ohta; Daniel Kolakofsky; Machiko Nishio
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

5.  Human parainfluenza virus type 2 L protein regions required for interaction with other viral proteins and mRNA capping.

Authors:  Machiko Nishio; Masato Tsurudome; Dominique Garcin; Hiroshi Komada; Morihiro Ito; Philippe Le Mercier; Tetsuya Nosaka; Daniel Kolakofsky
Journal:  J Virol       Date:  2010-11-10       Impact factor: 5.103

6.  Human parainfluenza virus type 2 V protein inhibits induction of tetherin.

Authors:  Keisuke Ohta; Yusuke Matsumoto; Natsuko Yumine; Machiko Nishio
Journal:  Med Microbiol Immunol       Date:  2017-04-28       Impact factor: 3.402

7.  Novel phosphoprotein-interacting region in Nipah virus nucleocapsid protein and its involvement in viral replication.

Authors:  Mio Omi-Furutani; Misako Yoneda; Kentaro Fujita; Fusako Ikeda; Chieko Kai
Journal:  J Virol       Date:  2010-07-28       Impact factor: 5.103

8.  Identification of RNA-binding regions on the P and V proteins of human parainfluenza virus type 2.

Authors:  Machiko Nishio; Masato Tsurudome; Morihiro Ito; Yasuhiko Ito
Journal:  Med Microbiol Immunol       Date:  2005-08-03       Impact factor: 3.402

9.  Human parainfluenza virus type 2 V protein inhibits genome replication by binding to the L protein: possible role in promoting viral fitness.

Authors:  Machiko Nishio; Junpei Ohtsuka; Masato Tsurudome; Tetsuya Nosaka; Daniel Kolakofsky
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

10.  A Point Mutation in the Human Parainfluenza Virus Type 2 Nucleoprotein Leads to Two Separate Effects on Virus Replication.

Authors:  Naoki Saka; Yusuke Matsumoto; Keisuke Ohta; Daniel Kolakofsky; Machiko Nishio
Journal:  J Virol       Date:  2021-12-08       Impact factor: 6.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.